{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T22:28:52Z","timestamp":1792621732309,"version":"4.5.0"},"reference-count":111,"publisher":"Oxford University Press (OUP)","issue":"1_suppl","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,4,1]]},"abstract":"<jats:p>The incidence of intracerebral hemorrhage (ICH) associated with oral anticoagulants (OAC) is about one in five cases of ICH and associated with severe clinical presentation, frequently rapid clinical deterioration, and 30-days mortality of app 50%. This narrative review gives an overview of presentation and acute treatment of OAC-ICH. Oral anticoagulants do not cause ICH but lead to prolongation of bleeding and higher risk of hematoma expansion (HE). Clinicoradiological characteristics of oral anticoagulant associated ICH are not different from ICH in general. The therapeutic principle of reversal is to prevent or limit HE. The mode of action of the reversal agents for vitamin K antagonists, direct oral thrombin inhibitor and direct oral factor Xa inhibitors are described in the main text. We also discuss the principles of blood pressure lowering in the setting of acute OAC-ICH as it may be the second driving force of HE. Stroke unit care is needed to prevent further complications. Data from randomized controlled trials and observational data from unselected patients are needed to make stronger and more precise recommendations on acute therapy.<\/jats:p>","DOI":"10.1177\/23969873231222393","type":"journal-article","created":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T07:00:24Z","timestamp":1747897224000},"page":"4-13","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["Principles of reversal of anticoagulation in patients with intracerebral hemorrhage related to oral anticoagulants"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7472-3194","authenticated-orcid":false,"given":"Hanne","family":"Christensen","sequence":"first","affiliation":[{"name":"Department of Neurology, Bispebjerg-Frederiksberg University Hospital, Kobenhavn, Denmark 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4199-995X","authenticated-orcid":false,"given":"Barbara","family":"Casolla","sequence":"additional","affiliation":[{"name":"Stroke Unit, CHU Pasteur 2, Universit\u00e9 Cote d\u2019Azur, UMR2CA URRIS), Nice, France 2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A","family":"Frontera","sequence":"additional","affiliation":[{"name":"Department of Neurology, NYU Langone Hospitals, New York, NY, USA 3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1006-1777","authenticated-orcid":false,"given":"Josefine","family":"Grundtvig","sequence":"additional","affiliation":[{"name":"Department of Neurology, Bispebjerg-Frederiksberg University Hospital, Kobenhavn, Denmark 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f8rn Dalsgaard","family":"Nielsen","sequence":"additional","affiliation":[{"name":"Centre for Excellence of Anticoagulant Therapy, Bispebjerg-Frederiksberg University Hospital, Frederiksberg, Denmark 4"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesper","family":"Petersson","sequence":"additional","affiliation":[{"name":"University of Lund, Lund, Sweden 5"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5080-8222","authenticated-orcid":false,"given":"Thorsten","family":"Steiner","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Lund, Lund, Sweden 6"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,4,1]]},"reference":[{"key":"2026012113080898700_bibr1-23969873231222393","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S1474-4422(21)00252-0","article-title":"Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"20","author":"Feigin","year":"2021","journal-title":"Lancet Neurol"},{"key":"2026012113080898700_bibr2-23969873231222393","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1177\/23969873211008770","article-title":"Trends in incidence of oral anticoagulant-related intracerebral hemorrhage and sales of oral anticoagulants in Capital Region of Denmark 2010\u20132017","volume":"6","author":"Grundtvig","year":"2021","journal-title":"Eur Stroke J"},{"key":"2026012113080898700_bibr3-23969873231222393","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1159\/000511603","article-title":"Time trends in intracerebral hemorrhage associated with oral anticoagulation and its risks factors in Spain from 2008 to 2015","volume":"84","author":"Quintas","year":"2021","journal-title":"Eur Neurol"},{"key":"2026012113080898700_bibr4-23969873231222393","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1007\/s00415-019-09536-1","article-title":"Meta-analysis of haematoma volume, haematoma expansion and mortality in intracerebral haemorrhage associated with oral anticoagulant use","volume":"266","author":"Seiffge","year":"2019","journal-title":"J Neurol"},{"key":"2026012113080898700_bibr5-23969873231222393","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1111\/j.1538-7836.2005.01419.x","article-title":"The vitamin K cycle","volume":"3","author":"Stafford","year":"2005","journal-title":"J Thromb Haemost"},{"key":"2026012113080898700_bibr6-23969873231222393","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1001\/archinte.163.20.2469","article-title":"Comparison of oral vs Intravenous phytonadione (vitamin K1) in patients with excessive anticoagulation: a prospective randomized controlled study","volume":"163","author":"Lubetsky","year":"2003","journal-title":"Arch Intern Med"},{"key":"2026012113080898700_bibr7-23969873231222393","first-page":"391","article-title":"Treatment of excessive anticoagulation with phytonadione (vitamin K): a meta-analysis","volume":"166","author":"DeZee","year":"2006","journal-title":"Arch Intern Med"},{"key":"2026012113080898700_bibr8-23969873231222393","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.thromres.2007.02.009","article-title":"Prothrombin complex concentrate (Octaplex\u00ae) in patients requiring immediate reversal of oral anticoagulation","volume":"121","author":"Riess","year":"2007","journal-title":"Thromb Res"},{"key":"2026012113080898700_bibr9-23969873231222393","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.thromres.2004.04.004","article-title":"Efficacy and safety of a prothrombin complex concentrate (Octaplex\u00ae) for rapid reversal of oral anticoagulation","volume":"113","author":"Lubetsky","year":"2004","journal-title":"Thromb Res"},{"key":"2026012113080898700_bibr10-23969873231222393","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/S1474-4422(16)00110-1","article-title":"Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage related to vitamin K antagonists (INCH): a randomised trial","volume":"15","author":"Steiner","year":"2016","journal-title":"Lancet Neurol"},{"key":"2026012113080898700_bibr11-23969873231222393","doi-asserted-by":"crossref","DOI":"10.3390\/ph15111437","article-title":"RADOA-Registry Investigators. Pharmacokinetics of phenprocoumon in emergency situations-results of the prospective observational RADOA-registry (reversal agent use in patients treated with direct oral anticoagulants or vitamin K antagonists registry)","volume":"15","author":"Lindhoff-Last","year":"2022","journal-title":"Pharmaceuticals"},{"key":"2026012113080898700_bibr12-23969873231222393","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1160\/TH09-11-0758","article-title":"Dabigatran etexilate - A novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity","volume":"103","author":"Van Ryn","year":"2010","journal-title":"Thromb Haemost"},{"key":"2026012113080898700_bibr13-23969873231222393","first-page":"189","article-title":"Reversing the new oral anticoagulants with prothrombin complex concentrates (PCCS): What is the evidence?","volume":"111","author":"Dickneite","year":"2013","journal-title":"Thromb Haemost"},{"key":"2026012113080898700_bibr14-23969873231222393","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1177\/2396987319849763","article-title":"European stroke organisation guideline on reversal of Oral Anticoagulants in acute intracerebral haemorrhage","volume":"4","author":"Christensen","year":"2019","journal-title":"Eur Stroke J"},{"key":"2026012113080898700_bibr15-23969873231222393","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1056\/NEJMoa1707278","article-title":"Idarucizumab for dabigatran reversal \u2014 full cohort analysis","volume":"377","author":"Pollack","year":"2017","journal-title":"New Engl J Med"},{"key":"2026012113080898700_bibr16-23969873231222393","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1007\/s11239-023-02772-3","article-title":"Standard operating procedure for idarucizumab reversal of dabigatran anticoagulation in ischemic and hemorrhagic stroke","volume":"55","author":"Frol","year":"2023","journal-title":"J Thromb Thrombolysis"},{"key":"2026012113080898700_bibr17-23969873231222393","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.666086","article-title":"Intravenous thrombolysis after dabigatran reversal by idarucizumab: a systematic review of the literature","volume":"12","author":"Frol","year":"2021","journal-title":"Front Neurol"},{"key":"2026012113080898700_bibr18-23969873231222393","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/1753944715605011","article-title":"Factor Xa inhibitors: A novel therapeutic class for the treatment of nonvalvular atrial fibrillation","volume":"10","author":"McCarty","year":"2016","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"2026012113080898700_bibr19-23969873231222393","doi-asserted-by":"crossref","DOI":"10.1186\/s40560-018-0303-y","article-title":"Safety of 4-factor prothrombin complex concentrate (4F-PCC) for emergent reversal of factor Xa inhibitors","volume":"6","author":"Tao","year":"2018","journal-title":"J Intensive Care"},{"key":"2026012113080898700_bibr20-23969873231222393","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1097\/CRD.0000000000000230","article-title":"Andexanet alfa for reversing factor Xa inhibition","volume":"27","author":"Sible","year":"2019","journal-title":"Cardiol Rev"},{"key":"2026012113080898700_bibr21-23969873231222393","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2147\/JBM.S121550","article-title":"Reversing factor xa inhibitors \u2013 clinical utility of andexanet alfa","volume":"8","author":"Kaatz","year":"2017","journal-title":"J Blood Med"},{"key":"2026012113080898700_bibr22-23969873231222393","author":"Trial of Andexanet alfa in ICrH Patients Receiving an Oral FXa Inhibitor [Internet]","year":"2019"},{"key":"2026012113080898700_bibr23-23969873231222393","unstructured":"AstraZeneca. Andexxa Phase IV trial stopped early after achieving pre-specified criteria on haemostatic efficacy versus usual care [Internet]. AstraZeneca.com, https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2023\/andexxa-phase-iv-trial-stopped-early-after-achieving-pre-specified-criteria-on-haemostatic-efficacy-versus-usual-care.html (2023, accessed 14 \u00a0Aug \u00a02023)"},{"key":"2026012113080898700_bibr24-23969873231222393","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1076029619863493","article-title":"Reversal of factor Xa inhibitors by andexanet alfa may increase thrombogenesis compared to pretreatment values","volume":"25","author":"Siddiqui","year":"2019","journal-title":"Clin Appl Thromb"},{"key":"2026012113080898700_bibr25-23969873231222393","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s12028-020-01161-5","article-title":"Andexanet alfa versus 4-factor prothrombin complex concentrate for reversal of factor Xa inhibitors in intracranial hemorrhage","volume":"35","author":"Ammar","year":"2021","journal-title":"Neurocrit Care"},{"key":"2026012113080898700_bibr26-23969873231222393","first-page":"899","article-title":"Increased use of oral anticoagulants in patients with atrial fibrillation: Temporal trends from 2005 to 2015 in Denmark","volume":"38","author":"Gadsb\u00f8ll","year":"2017","journal-title":"Eur Heart J"},{"key":"2026012113080898700_bibr27-23969873231222393","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamanetworkopen.2022.42964","article-title":"Trends in use of oral anticoagulants in older adults with newly diagnosed atrial fibrillation, 2010-2020","volume":"5","author":"Ko","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2026012113080898700_bibr28-23969873231222393","unstructured":"Roser M, Ritchie H. Age Structure - Our World in Data [Internet]. Our World in Data, https:\/\/ourworldindata.org\/age-structure#citation (2019, accessed 5 Apr 2023)"},{"key":"2026012113080898700_bibr29-23969873231222393","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S0140-6736(14)61774-8","article-title":"50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study","volume":"386","author":"Schnabel","year":"2015","journal-title":"Lancet"},{"key":"2026012113080898700_bibr30-23969873231222393","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanepe.2022.100386","article-title":"Temporal trends and patterns in atrial fibrillation incidence: a population-based study of 3\u00b74 million individuals","volume":"17","author":"Wu","year":"2022","journal-title":"The Lancet Regional Health - Europe"},{"key":"2026012113080898700_bibr31-23969873231222393","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.14874","article-title":"Trends in atrial fibrillation incidence rates within an integrated health care delivery system, 2006 to 2018","volume":"3","author":"Williams","year":"2020","journal-title":"JAMA Netw Open"},{"key":"2026012113080898700_bibr32-23969873231222393","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"New Engl J Med"},{"key":"2026012113080898700_bibr33-23969873231222393","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"New Engl J Med"},{"key":"2026012113080898700_bibr34-23969873231222393","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"New Engl J Med"},{"key":"2026012113080898700_bibr35-23969873231222393","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"New Engl J Med"},{"key":"2026012113080898700_bibr36-23969873231222393","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-018905","article-title":"UK GARFIELD-AF Investigators and GARFIELD-AF Steering Committee. Temporal trends in antithrombotic treatment of real-world UK patients with newly diagnosed atrial fibrillation: findings from the GARFIELD-AF registry","volume":"8","author":"Apenteng","year":"2018","journal-title":"BMJ Open"},{"key":"2026012113080898700_bibr37-23969873231222393","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"2026012113080898700_bibr38-23969873231222393","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1161\/STROKEAHA.112.650614","article-title":"Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial","volume":"43","author":"Hart","year":"2012","journal-title":"Stroke"},{"key":"2026012113080898700_bibr39-23969873231222393","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1161\/STROKEAHA.113.004506","article-title":"ROCKET AF Steering Committee and Investigators. Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation","volume":"45","author":"Hankey","year":"2014","journal-title":"Stroke"},{"key":"2026012113080898700_bibr40-23969873231222393","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1182\/blood-2016-08-731638","article-title":"Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation therapy","volume":"129","author":"Lopes","year":"2017","journal-title":"Blood"},{"key":"2026012113080898700_bibr41-23969873231222393","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1161\/STROKEAHA.120.030930","article-title":"Prognosis of intracerebral hemorrhage related to antithrombotic use: an observational study from the Swedish Stroke Register (Riksstroke)","volume":"52","author":"Apostolaki-Hansson","year":"2021","journal-title":"Stroke"},{"key":"2026012113080898700_bibr42-23969873231222393","doi-asserted-by":"crossref","DOI":"10.1016\/j.clineuro.2020.106146","article-title":"Intracerebral hemorrhage outcomes in patients using direct oral anticoagulants versus vitamin K antagonists: a meta-analysis","volume":"198","author":"Ahmed","year":"2020","journal-title":"Clin Neurol Neurosurg"},{"key":"2026012113080898700_bibr43-23969873231222393","doi-asserted-by":"crossref","first-page":"e1143","DOI":"10.1212\/WNL.0000000000005207","article-title":"Comparing intracerebral hemorrhages associated with direct oral anticoagulants or warfarin","volume":"90","author":"Kurogi","year":"2018","journal-title":"Neurology"},{"key":"2026012113080898700_bibr44-23969873231222393","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1161\/STROKEAHA.118.023492","article-title":"Characteristics in Non\u2013Vitamin K antagonist oral anticoagulant\u2013related intracerebral hemorrhage","volume":"50","author":"Gerner","year":"2019","journal-title":"Stroke"},{"key":"2026012113080898700_bibr45-23969873231222393","first-page":"288","article-title":"Sex-Differences in oral anticoagulant-related intracerebral hemorrhage","volume":"13","author":"Grundtvig","year":"2022","journal-title":"Front Neurol"},{"key":"2026012113080898700_bibr46-23969873231222393","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0140-6736(10)60834-3","article-title":"Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study","volume":"376","author":"O\u2019Donnell","year":"2010","journal-title":"Lancet"},{"key":"2026012113080898700_bibr47-23969873231222393","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0140-6736(16)30506-2","article-title":"Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study","volume":"388","author":"O\u2019Donnell","year":"2016","journal-title":"Lancet"},{"key":"2026012113080898700_bibr48-23969873231222393","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1136\/jnnp-2020-325299","article-title":"Small vessel disease burden and intracerebral haemorrhage in patients taking oral anticoagulants","volume":"92","author":"Seiffge","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2026012113080898700_bibr49-23969873231222393","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1161\/STROKEAHA.112.661603","article-title":"SMASH-U: a proposal for etiologic classification of intracerebral hemorrhage","volume":"43","author":"Meretoja","year":"2012","journal-title":"Stroke"},{"key":"2026012113080898700_bibr50-23969873231222393","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0156992","article-title":"The H-ATOMIC criteria for the etiologic classification of patients with intracerebral hemorrhage","volume":"11","author":"Mart\u00ed-F\u00e0bregas","year":"2016","journal-title":"PLoS One"},{"key":"2026012113080898700_bibr51-23969873231222393","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1212\/WNL.55.7.907","article-title":"What causes intracerebral hemorrhage during warfarin therapy?","volume":"55","author":"Hart","year":"2000","journal-title":"Neurology"},{"key":"2026012113080898700_bibr52-23969873231222393","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1161\/01.STR.0000196989.09900.f8","article-title":"Intracerebral hemorrhage associated with oral anticoagulant therapy: current practices and unresolved questions","volume":"37","author":"Steiner","year":"2006","journal-title":"Stroke"},{"key":"2026012113080898700_bibr53-23969873231222393","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1001\/archinte.164.8.880","article-title":"The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage","volume":"164","author":"Rosand","year":"2004","journal-title":"Arch Intern Med"},{"key":"2026012113080898700_bibr54-23969873231222393","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1001\/archinte.1994.00420130036007","volume":"154","author":"Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials","year":"1994","journal-title":"Arch Intern Med"},{"key":"2026012113080898700_bibr55-23969873231222393","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1007\/s12028-017-0403-x","article-title":"Coagulation testing in intracerebral hemorrhage related to non-vitamin K antagonist oral anticoagulants","volume":"27","author":"Purrucker","year":"2017","journal-title":"Neurocrit Care"},{"key":"2026012113080898700_bibr56-23969873231222393","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1002\/ana.25165","article-title":"When less is more (brain)-comment on \u201cRivaroxaban plasma levels in acute ischemic stroke and intracerebral hemorrhage\u201d","volume":"83","author":"Seiffge","year":"2018","journal-title":"Ann Neurol"},{"key":"2026012113080898700_bibr57-23969873231222393","doi-asserted-by":"crossref","first-page":"E782","DOI":"10.1212\/WNL.0000000000006958","article-title":"Hematoma location and morphology of anticoagulation-associated intracerebral hemorrhage","volume":"92","author":"Seiffge","year":"2019","journal-title":"Neurology"},{"key":"2026012113080898700_bibr58-23969873231222393","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1161\/STROKEAHA.112.672303","article-title":"Vitamin K antagonists-associated cerebral hemorrhages: what are their characteristics?","volume":"44","author":"Dequatre-Ponchelle","year":"2013","journal-title":"Stroke"},{"key":"2026012113080898700_bibr59-23969873231222393","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.37438","article-title":"Clinical characteristics and outcomes associated with oral anticoagulant use among patients hospitalized with intracerebral hemorrhage","volume":"4","author":"Xian","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2026012113080898700_bibr60-23969873231222393","doi-asserted-by":"crossref","first-page":"6589","DOI":"10.1007\/s00415-022-11333-2","article-title":"Clinical and neuroimaging risk factors associated with the development of intracerebral hemorrhage while taking direct oral anticoagulants","volume":"269","author":"Das","year":"2022","journal-title":"J Neurol"},{"key":"2026012113080898700_bibr61-23969873231222393","doi-asserted-by":"crossref","first-page":"E282","DOI":"10.1161\/STR.0000000000000407","article-title":"American Heart Association\/American Stroke Association. 2022 guideline for the management of patients with spontaneous intracerebral hemorrhage: a guideline from the American Heart Association\/American Stroke Association","volume":"53","author":"Greenberg","year":"2022","journal-title":"Stroke"},{"key":"2026012113080898700_bibr62-23969873231222393","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/ana.26519","article-title":"A causal classification system for intracerebral hemorrhage subtypes","volume":"93","author":"Raposo","year":"2023","journal-title":"Ann Neurol"},{"key":"2026012113080898700_bibr63-23969873231222393","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1161\/STROKEAHA.122.041764","article-title":"Genetic risk score improves risk stratification for anticoagulation-related intracerebral hemorrhage","volume":"54","author":"Mayerhofer","year":"2023","journal-title":"Stroke"},{"key":"2026012113080898700_bibr64-23969873231222393","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1161\/STROKEAHA.120.028310","article-title":"Combining imaging and genetics to predict recurrence of anticoagulation-associated intracerebral hemorrhage","volume":"51","author":"Biffi","year":"2020","journal-title":"Stroke"},{"key":"2026012113080898700_bibr65-23969873231222393","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1001\/jama.2017.21917","article-title":"Association of intracerebral hemorrhage among patients taking non-Vitamin K antagonist vs vitamin K antagonist oral anticoagulants with in-hospital mortality","volume":"319","author":"Inohara","year":"2018","journal-title":"JAMA"},{"key":"2026012113080898700_bibr66-23969873231222393","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1111\/ene.13742","article-title":"Fatal oral anticoagulant-related intracranial hemorrhage: a systematic review and meta-analysis","volume":"25","author":"Katsanos","year":"2018","journal-title":"Eur J Neurol"},{"key":"2026012113080898700_bibr67-23969873231222393","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1161\/STROKEAHA.116.013343","article-title":"Anticoagulant-associated intracranial hemorrhage in the era of reversal agents","volume":"48","author":"Steiner","year":"2017","journal-title":"Stroke"},{"key":"2026012113080898700_bibr68-23969873231222393","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1212\/01.wnl.0000339060.11702.dd","article-title":"Cerebral microbleeds are a risk factor for warfarin-related intracerebral hemorrhage","volume":"72","author":"Lee","year":"2009","journal-title":"Neurology"},{"key":"2026012113080898700_bibr69-23969873231222393","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1002\/acn3.50834","article-title":"Microbleed prevalence and burden in anticoagulant-associated intracerebral bleed","volume":"6","author":"Lioutas","year":"2019","journal-title":"Ann Clin Transl Neurol"},{"key":"2026012113080898700_bibr70-23969873231222393","doi-asserted-by":"crossref","first-page":"e2432","DOI":"10.1212\/WNL.0000000000007532","article-title":"MRI predicts intracranial hemorrhage in patients who receive long-term oral anticoagulation","volume":"92","author":"Mart\u00ed-F\u00e0bregas","year":"2019","journal-title":"Neurology"},{"key":"2026012113080898700_bibr71-23969873231222393","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1212\/WNL.0000000000004704","article-title":"International META-MICROBLEEDS Initiative. Brain microbleeds, anticoagulation, and hemorrhage risk: meta-analysis in stroke patients with AF","volume":"89","author":"Charidimou","year":"2017","journal-title":"Neurology"},{"key":"2026012113080898700_bibr72-23969873231222393","first-page":"1222","article-title":"Antithrombotic drug use, cerebral microbleeds, and intracerebral hemorrhage: A systematic review of published and unpublished studies","volume-title":"Stroke","author":"Lovelock","year":"2010"},{"key":"2026012113080898700_bibr73-23969873231222393","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1136\/jnnp-2018-319104","article-title":"Risk of intracerebral haemorrhage in Chinese patients with atrial fibrillation on warfarin with cerebral microbleeds: the IPAAC-Warfarin study","volume":"90","author":"Soo","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2026012113080898700_bibr74-23969873231222393","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S1474-4422(18)30145-5","article-title":"Cerebral microbleeds and intracranial haemorrhage risk in patients anticoagulated for atrial fibrillation after acute ischaemic stroke or transient ischaemic attack (CROMIS-2): a multicentre observational cohort study","volume":"17","author":"Wilson","year":"2018","journal-title":"Lancet Neurol"},{"key":"2026012113080898700_bibr75-23969873231222393","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1177\/1747493017751931","article-title":"Clinical significance of cerebral microbleeds on MRI: a comprehensive meta-analysis of risk of intracerebral hemorrhage, ischemic stroke, mortality, and dementia in cohort studies (v1)","volume":"13","author":"Charidimou","year":"2018","journal-title":"Int J Stroke"},{"key":"2026012113080898700_bibr76-23969873231222393","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-002575","article-title":"Microbleeds as a predictor of intracerebral haemorrhage and ischaemic stroke after a TIA or minor ischaemic stroke: a cohort study","volume":"3","author":"Kwa","year":"2013","journal-title":"BMJ Open"},{"key":"2026012113080898700_bibr77-23969873231222393","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S1474-4422(21)00024-7","article-title":"Development of imaging-based risk scores for prediction of intracranial haemorrhage and ischaemic stroke in patients taking antithrombotic therapy after ischaemic stroke or transient ischaemic attack: a pooled analysis of individual patient data from coho","volume":"20","author":"Best","year":"2021","journal-title":"Lancet Neurol"},{"key":"2026012113080898700_bibr78-23969873231222393","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1001\/jamaneurol.2013.98","article-title":"Predictors of hematoma volume in deep and lobar supratentorial intracerebral hemorrhage","volume":"70","author":"Falcone","year":"2013","journal-title":"JAMA Neurol"},{"key":"2026012113080898700_bibr79-23969873231222393","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1161\/STROKEAHA.118.021979","article-title":"Clinical outcomes and neuroimaging profiles in nondisabled patients with anticoagulant-related intracerebral hemorrhage","volume":"49","author":"Lioutas","year":"2018","journal-title":"Stroke"},{"key":"2026012113080898700_bibr80-23969873231222393","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S1474-4422(18)30253-9","article-title":"Absolute risk and predictors of the growth of acute spontaneous intracerebral haemorrhage: a systematic review and meta-analysis of individual patient data","volume":"17","author":"Al-Shahi Salman","year":"2018","journal-title":"Lancet Neurol"},{"key":"2026012113080898700_bibr81-23969873231222393","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1161\/STROKEAHA.114.006661","article-title":"Characteristics of intracerebral hemorrhage during rivaroxaban treatment: comparison with those during warfarin","volume":"45","author":"Hagii","year":"2014","journal-title":"Stroke"},{"key":"2026012113080898700_bibr82-23969873231222393","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1212\/WNL.0000000000003886","article-title":"Outcome of intracerebral hemorrhage associated with different oral anticoagulants","volume":"88","author":"Wilson","year":"2017","journal-title":"Neurology"},{"key":"2026012113080898700_bibr83-23969873231222393","doi-asserted-by":"crossref","first-page":"738","DOI":"10.3324\/haematol.2017.182220","article-title":"A three-year prospective study of the presentation and clinical outcomes of major bleeding episodes associated with oral anticoagulant use in the uk (Orange study)","volume":"103","author":"Green","year":"2018","journal-title":"Haematologica"},{"key":"2026012113080898700_bibr84-23969873231222393","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fneur.2021.794001","article-title":"Decision-making process for the management of acute stroke in patients on oral anticoagulant: from guidelines to clinical routine","volume":"12","author":"Sibon","year":"2022","journal-title":"Front Neurol"},{"key":"2026012113080898700_bibr85-23969873231222393","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1001\/jamaneurol.2015.3682","article-title":"Early clinical and radiological course, management, and outcome of intracerebral hemorrhage related to new oral anticoagulants","volume":"73","author":"Purrucker","year":"2016","journal-title":"JAMA Neurol"},{"key":"2026012113080898700_bibr86-23969873231222393","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1161\/STROKEAHA.122.040143","article-title":"Mechanism of spontaneous intracerebral Hemorrhage Formation: an anatomical specimens-based study","volume":"53","author":"Rzepli\u0144ski","year":"2022","journal-title":"Stroke"},{"key":"2026012113080898700_bibr87-23969873231222393","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.028336","article-title":"Antithrombotic treatment, prehospital blood pressure, and outcomes in spontaneous intracerebral hemorrhage","volume":"12","author":"Larsen","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"2026012113080898700_bibr88-23969873231222393","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1001\/jama.2015.0846","article-title":"Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage","volume":"313","author":"Kuramatsu","year":"2015","journal-title":"JAMA"},{"key":"2026012113080898700_bibr89-23969873231222393","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1161\/STROKEAHA.113.003608","article-title":"Time course of early postadmission hematoma expansion in spontaneous intracerebral hemorrhage","volume":"45","author":"Ovesen","year":"2014","journal-title":"Stroke"},{"key":"2026012113080898700_bibr90-23969873231222393","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1161\/STROKEAHA.108.524470","article-title":"Can a subset of intracerebral hemorrhage patients benefit from hemostatic therapy with recombinant activated factor vii?","volume":"40","author":"Mayer","year":"2009","journal-title":"Stroke"},{"key":"2026012113080898700_bibr91-23969873231222393","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1161\/STROKEAHA.121.034572","article-title":"Hematoma expansion and clinical outcomes in patients with factor-Xa inhibitor-related atraumatic intracerebral hemorrhage treated within the ANNEXA-4 trial versus real-world usual care","volume":"53","author":"Huttner","year":"2022","journal-title":"Stroke"},{"key":"2026012113080898700_bibr92-23969873231222393","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1227\/01.NEU.0000232837.34992.32","article-title":"Dynamics of intraventricular hemorrhage in patients with spontaneous intracerebral hemorrhage: Risk factors, clinical impact, and effect of hemostatic therapy with recombinant activated factor VII","volume":"59","author":"Steiner","year":"2006","journal-title":"Neurosurg"},{"key":"2026012113080898700_bibr93-23969873231222393","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1161\/STROKEAHA.119.027451","article-title":"Redefining hematoma expansion with the inclusion of intraventricular hemorrhage growth","volume":"51","author":"Yogendrakumar","year":"2020","journal-title":"Stroke"},{"key":"2026012113080898700_bibr94-23969873231222393","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S1474-4422(12)70038-8","article-title":"Prediction of haematoma growth and outcome in patients with intracerebral haemorrhage using the CT-angiography spot sign (PREDICT): a prospective observational study","volume":"11","author":"Demchuk","year":"2012","journal-title":"Lancet Neurol"},{"key":"2026012113080898700_bibr95-23969873231222393","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/1471-2377-12-109","article-title":"Swirl sign in intracerebral haemorrhage: definition, prevalence, reliability and prognostic value","volume":"12","author":"Selariu","year":"2012","journal-title":"BMC Neurol"},{"key":"2026012113080898700_bibr96-23969873231222393","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1212\/WNL.0000000000005571","article-title":"Author response: Blood pressure reduction and noncontrast CT markers of intracerebral hemorrhage expansion","volume":"90","author":"Morotti","year":"2018","journal-title":"Neurology"},{"key":"2026012113080898700_bibr97-23969873231222393","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1212\/WNL.0000000000010660","article-title":"Noncontrast CT markers of intracerebral hemorrhage expansion and poor outcome: a meta-analysis","volume":"95","author":"Morotti","year":"2020","journal-title":"Neurology"},{"key":"2026012113080898700_bibr98-23969873231222393","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1161\/01.STR.0000221786.81354.d6","article-title":"Hematoma growth and outcome in treated neurocritical care patients with intracerebral hemorrhage related to oral anticoagulant therapy: comparison of acute treatment strategies using vitamin K, fresh frozen plasma, and prothrombin complex concentrates","volume":"37","author":"Huttner","year":"2006","journal-title":"Stroke"},{"key":"2026012113080898700_bibr99-23969873231222393","doi-asserted-by":"crossref","first-page":"E2054","DOI":"10.1212\/WNL.0000000000012856","article-title":"Modeling the clinical implications of andexanet Alfa in Factor Xa inhibitor-associated intracerebral hemorrhage","volume":"97","author":"Chuck","year":"2021","journal-title":"Neurology"},{"key":"2026012113080898700_bibr100-23969873231222393","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/ana.24416","article-title":"Reversal strategies for vitamin K antagonists in acute intracerebral hemorrhage","volume":"78","author":"Parry-Jones","year":"2015","journal-title":"Ann Neurol"},{"key":"2026012113080898700_bibr101-23969873231222393","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1016\/j.jacc.2021.04.061","article-title":"Meta-analysis of reversal agents for severe bleeding associated with direct oral anticoagulants","volume":"77","author":"G\u00f3mez-Outes","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026012113080898700_bibr102-23969873231222393","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s12028-015-0222-x","article-title":"Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the neurocritical care society and society of critical care medicine","volume":"24","author":"Frontera","year":"2016","journal-title":"Neurocrit Care"},{"key":"2026012113080898700_bibr103-23969873231222393","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1093\/eurheartj\/ehy056","article-title":"Management of therapeutic anticoagulation in patients with intracerebral haemorrhage and mechanical heart valves","volume":"39","author":"Kuramatsu","year":"2018","journal-title":"Eur Heart J"},{"key":"2026012113080898700_bibr104-23969873231222393","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1161\/STROKEAHA.118.024449","article-title":"Five-year risk of major ischemic and hemorrhagic events after intracerebral hemorrhage","volume":"50","author":"Casolla","year":"2019","journal-title":"Stroke"},{"key":"2026012113080898700_bibr105-23969873231222393","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1161\/STROKEAHA.110.593087","article-title":"Optimal timing of resumption of warfarin after intracranial hemorrhage","volume":"41","author":"Majeed","year":"2010","journal-title":"Stroke"},{"key":"2026012113080898700_bibr106-23969873231222393","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1136\/jnnp-2020-323079","article-title":"Longer term stroke risk in intracerebral haemorrhage survivors","volume":"91","author":"Banerjee","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2026012113080898700_bibr107-23969873231222393","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.athoracsur.2019.01.016","article-title":"Reversal and resumption of antithrombotic therapy in LVAD-Associated intracranial hemorrhage","volume":"108","author":"Cho","year":"2019","journal-title":"Ann Thorac Surg"},{"key":"2026012113080898700_bibr108-23969873231222393","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1161\/STROKEAHA.118.023797","article-title":"Non-Vitamin K antagonist oral anticoagulants versus warfarin in atrial fibrillation patients with intracerebral hemorrhage","volume":"50","author":"Nielsen","year":"2019","journal-title":"Stroke"},{"key":"2026012113080898700_bibr109-23969873231222393","doi-asserted-by":"crossref","DOI":"10.1177\/23969873211012133","article-title":"European Stroke Organisation (ESO) guidelines on blood pressure management in acute ischaemic stroke and intracerebral haemorrhage","volume":"6","author":"Sandset","year":"2021","journal-title":"Eur Stroke J"},{"key":"2026012113080898700_bibr110-23969873231222393","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/S1474-4422(19)30196-6","article-title":"Blood pressure control and clinical outcomes in acute intracerebral haemorrhage: a preplanned pooled analysis of individual participant data","volume":"18","author":"Moullaali","year":"2019","journal-title":"Lancet Neurol"},{"key":"2026012113080898700_bibr111-23969873231222393","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(23)00806-1","article-title":"The third intensive care bundle with blood pressure reduction in acute cerebral haemorrhage trial (INTERACT3): an international, stepped wedge cluster randomised controlled trial","volume":"402","author":"Ma","year":"2023","journal-title":"Lancet"}],"container-title":["European Stroke Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/23969873231222393","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/23969873231222393","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/esj\/article-pdf\/10\/1_suppl\/4\/64645605\/23969873231222393.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/esj\/article-pdf\/10\/1_suppl\/4\/64645605\/23969873231222393.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T18:08:47Z","timestamp":1769018927000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/esj\/article\/10\/1_suppl\/4\/8268619"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,1]]},"references-count":111,"journal-issue":{"issue":"1_suppl","published-print":{"date-parts":[[2025,4,1]]}},"URL":"https:\/\/doi.org\/10.1177\/23969873231222393","relation":{},"ISSN":["2396-9873","2396-9881"],"issn-type":[{"value":"2396-9873","type":"print"},{"value":"2396-9881","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,4,1]]},"published":{"date-parts":[[2025,4,1]]}}}